重复FNA细胞学不确定甲状腺结节的危险分层:分子检测与监测的意义
本研究回顾性分析691例初次FNA为AUS或FN的甲状腺结节,重复FNA时行细胞学与Afirma分子检测。重复FNA为ND的结节NIFTP和/或癌患病率为9%(95%CI 0.042-0.182),介于良性(5%)与AUS/FN(18%)之间但无统计学差异;ND结节Afirma检测失败率低,可能受益于分子检测。
要点
- 重复FNA为ND的AUS/FN结节NIFTP和/或癌风险为9%,低但不可忽略。
- 重复FNA为良性的AUS/FN结节风险仅5%,可能无需分子检测。
- ND结节Afirma检测成功率91%,支持在该亚组行分子检测。
核心结论
- 重复FNA为ND的AUS/FN结节NIFTP和/或癌风险低但不可忽略,可能受益于分子检测。
- 重复FNA为良性的AUS/FN结节NIFTP和/或癌风险极低,可能无需分子检测。
研究设计与样本
- 回顾性单中心研究,纳入2013年6月至2021年7月初次FNA为AUS或FN并重复FNA行细胞学与Afirma检测的成人甲状腺结节。
- 共691个AUS和FN结节接受重复FNA和Afirma检测。
主要发现
- 总体98%病例获得诊断性Afirma结果,重复FNA为ND的结节中91%获得诊断性结果。
- 重复FNA为ND的结节NIFTP和/或癌患病率为9%(95%CI 0.042-0.182)。
- 重复FNA为良性的结节患病率为5%(95%CI 0.029-0.094),重复FNA为AUS或FN的结节为18%(95%CI 0.140-0.218)。
关键数值与推荐
- 重复FNA为ND的结节NIFTP和/或癌患病率9%(95%CI 0.042-0.182)。
- 重复FNA为良性的结节患病率5%(95%CI 0.029-0.094)。
- 重复FNA为AUS或FN的结节患病率18%(95%CI 0.140-0.218)。
- ND结节Afirma检测诊断性结果获得率91%。
临床怎么用
- 对重复FNA为ND的AUS/FN结节可考虑分子检测以辅助危险分层。
- 对重复FNA为良性的AUS/FN结节分子检测获益可能性低。
局限性
- 回顾性单中心设计可能限制外推性。
- ND组与良性组及AUS/FN组的患病率差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence guiding the management of cytologically indeterminate thyroid nodules with nondiagnostic (ND) or benign cytology on repeat fine-needle aspiration (FNA) is limited. This study evaluates the utility of molecular testing and estimates the risk of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and cancer among such nodules. METHODS: This was a retrospective single-institution review of thyroid nodules from adults that were classified as atypia of undetermined significance (AUS) or follicular neoplasm (FN) on initial FNA and underwent repeat FNA for cytology and Afirma testing (June 2013-July 2021). The association between repeat FNA cytology and RNA yield for Afirma was determined. Histologic outcomes were integrated with Afirma results to define end points for each nodule. RESULTS: A total of 691 AUS and FN nodules underwent repeat FNA and Afirma testing. Diagnostic Afirma results were obtained in 98% of cases overall and in 91% of nodules with ND cytology on repeat FNA. Using combined molecular and histologic end points, the NIFTP and/or cancer prevalence for nodules with ND cytology on repeat FNA was 9% (95% confidence interval [CI], 0.042-0.182), falling between those nodules classified as benign (5%; 95% CI, 0.029-0.094) and those classified as AUS or FN (18%; 95% CI, 0.140-0.218) on repeat FNA, although not reaching statistical significance from either subgroup (p = .38 and .10, respectively). CONCLUSIONS: AUS and FN nodules that are ND on repeat FNA have low but nonnegligible risk of NIFTP and/or cancer and may benefit from molecular testing, given the low test failure rate in this subgroup. Conversely, AUS and FN nodules reclassified as benign on repeat FNA have a very low risk of NIFTP and/or cancer and are unlikely to benefit from molecular testing.
引用
- Hall EA, Hartzband P, VanderLaan PA, et al. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance. Cancer Cytopathol. 2023. PMID: 36792948. doi:10.1002/cncy.22684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。